Company intelligence / Profile preview

Virtuoso Therapeutics

San Mateo, California, USAvirtuosotherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Virtuoso Therapeutics is advancing a pipeline of novel bispecific antibodies for oncology indications. Their lead program targets CD38 x ICAM‑1 for hematologic malignancies and has reached early clinical development. Other programs targeting the CD47 axis are in preclinical stages. The company aims to address limitations of current therapies by improving potency, selectivity, and therapeutic window through its proprietary technology platform. No published late-stage or commercial results as of now[2][3][5].

Therapeutic areas: HematologyOncology
Modalities: Bispecific antibodiesAntibody drug conjugates (ADC)Biological products[3][6]
Industry: Biotech

Drug pipeline

9 assets

VP301

Preclinical

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Virtuoso Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virtuoso Therapeutics.

Explore the full profile